Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, June 2, 2023
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
Matthew Biegler Initiated (ACRV) at Buy and Held Target at $25 on, Jun 2nd, 2023
Matthew Biegler of Oppenheimer, Initiated "Acrivon Therapeutics, Inc." (ACRV) at Buy and Held Target at $25 on, Jun 2nd, 2023.
Matthew has made no other calls on ACRV in the last 4 months.
There are 2 other peers that have a rating on ACRV. Out of the 2 peers that are also analyzing ACRV, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Matthew
- Etzer Darout of "BMO Capital" Initiated at Buy and Held Target at $25 on, Monday, May 8th, 2023
- Emily Bodnar of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $24 on, Tuesday, May 2nd, 2023
